Literature DB >> 34618307

Primary antibody deficiencies in Turkey: molecular and clinical aspects.

Sinem Firtina1,2, Yuk Yin Ng3, Ozden H Ng4, Ayca Kiykim5, Esra Yucel Ozek6, Manolya Kara7, Elif Aydiner8, Serdar Nepesov9, Yildiz Camcioglu5, Esra H Sayar10, Ezgi Yalcin Gungoren8, Ismail Reisli10, Selda H Torun6, Sule Haskologlu11, Tuba Cogurlu12, Aysenur Kaya7, Sukru Cekic13, Safa Baris8, Ugur Ozbek14, Ahmet Ozen8, Muge Sayitoglu15,16.   

Abstract

Primary antibody deficiencies (PAD) are the most common subtype of primary immunodeficiencies, characterized by increased susceptibility to infections and autoimmunity, allergy, or malignancy predisposition. PAD syndromes comprise of immune system genes highlighted the key role of B cell activation, proliferation, migration, somatic hypermutation, or isotype switching have a wide spectrum from agammaglobulinemia to selective Ig deficiency. In this study, we describe the molecular and the clinical aspects of fifty-two PAD patients. The most common symptoms of our cohort were upper and lower respiratory infections, bronchiectasis, diarrhea, and recurrent fever. Almost all patients (98%) had at least one of the symptoms like autoimmunity, lymphoproliferation, allergy, or gastrointestinal disease. A custom-made next-generation sequencing (NGS) panel, which contains 24 genes, was designed to identify well-known disease-causing variants in our cohort. We identified eight variants (15.4%) among 52 PAD patients. The variants mapped to BTK (n = 4), CD40L (n = 1), ICOS (n = 1), IGHM (n = 1), and TCF3 (n = 1) genes. Three novel variants were described in the BTK (p.G414W), ICOS (p.G60*), and IGHM (p.S19*) genes. We performed Sanger sequencing to validate pathogenic variants and check for allelic segregation in the family. Targeted NGS panel sequencing can be beneficial as a suitable diagnostic modality for diagnosing well-known monogenic PAD diseases (only 2-10% of PADs); however, screening only the coding regions of the genome may not be adequately powered to solve the pathogenesis of PAD in all cases. Deciphering the regulatory regions of the genome and better understanding the epigenetic modifications will elucidate the molecular basis of complex PADs.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Common variable immune deficiency; Primary antibody deficiencies; Targeted next-generation sequencing

Mesh:

Year:  2021        PMID: 34618307     DOI: 10.1007/s12026-021-09242-z

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  39 in total

1.  Population prevalence of diagnosed primary immunodeficiency diseases in the United States.

Authors:  J M Boyle; R H Buckley
Journal:  J Clin Immunol       Date:  2007-06-19       Impact factor: 8.317

Review 2.  Primary antibody deficiencies.

Authors:  Anne Durandy; Sven Kracker; Alain Fischer
Journal:  Nat Rev Immunol       Date:  2013-06-14       Impact factor: 53.106

3.  The Clinical and Immunological Features of Patients with Primary Antibody Deficiencies.

Authors:  Gholamreza Azizi; Yasser Bagheri; Marzieh Tavakol; Forough Askarimoghaddam; Kumars Porrostami; Hosein Rafiemanesh; Reza Yazdani; Fatemeh Kiaee; Sima Habibi; Kosar Abouhamzeh; Hamed Mohammadi; Mostafa Qorbani; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2018       Impact factor: 2.895

Review 4.  Common Variable Immunodeficiency: Epidemiology, Pathogenesis, Clinical Manifestations, Diagnosis, Classification, and Management.

Authors:  R Yazdani; S Habibi; L Sharifi; G Azizi; H Abolhassani; P Olbrich; A Aghamohammadi
Journal:  J Investig Allergol Clin Immunol       Date:  2019-02-11       Impact factor: 4.333

Review 5.  Management of primary antibody deficiency syndromes.

Authors:  Vincent R Bonagura; Blanka Kaplan; Artemio M Jongco
Journal:  Ann Allergy Asthma Immunol       Date:  2016-12       Impact factor: 6.347

6.  An update on X-Linked agammaglobulinaemia: clinical manifestations and management.

Authors:  Benjamin Martin James Shillitoe; Andrew R Gennery
Journal:  Curr Opin Allergy Clin Immunol       Date:  2019-12

7.  Monogenic Primary Immunodeficiency Disorder Associated with Common Variable Immunodeficiency and Autoimmunity.

Authors:  Mohammad Hossein Asgardoon; Gholamreza Azizi; Reza Yazdani; Mahsa Sohani; Salar Pashangzadeh; Arash Kalantari; Mansoureh Shariat; Alireza Shafiei; Fereshte Salami; Mahnaz Jamee; Seyed Erfan Rasouli; Javad Mohammadi; Gholamreza Hassanpour; Marziyeh Tavakol; Zahra Chavoshzadeh; Seyed Alireza Mahdaviani; Tooba Momen; Nasrin Behniafard; Mohammad Nabavi; Mohammad Hassan Bemanian; Saba Arshi; Rasol Molatefi; Roya Sherkat; Afshin Shirkani; Soheila Alyasin; Farahzad Jabbari-Azad; Javad Ghaffari; Mehrnaz Mesdaghi; Hamid Ahanchian; Maryam Khoshkhui; Mohammad Hossein Eslamian; Taher Cheraghi; Abbas Dabbaghzadeh; Rasoul Nasiri Kalmarzi; Hossein Esmaeilzadeh; Javad Tafaroji; Abbas Khalili; Mahnaz Sadeghi-Shabestari; Sepideh Darougar; Mojgan Moghtaderi; Akefeh Ahmadiafshar; Behzad Shakerian; Marzieh Heidarzadeh; Babak Ghalebaghi; Seyed Mohammad Fathi; Behzad Darabi; Morteza Fallahpour; Azam Mohsenzadeh; Sarehsadat Ebrahimi; Samin Sharafian; Ahmad Vosughimotlagh; Mitra Tafakoridelbari; Maziyar Rahimi Haji-Abadi; Parisa Ashournia; Anahita Razaghian; Arezou Rezaei; Samaneh Delavari; Paniz Shirmast; Fateme Babaha; Ashraf Samavat; Setareh Mamishi; Hossein Ali Khazaei; Babak Negahdari; Nima Rezaei; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  Int Arch Allergy Immunol       Date:  2020-07-02       Impact factor: 2.749

8.  Comparison of clinical and immunological features and mortality in common variable immunodeficiency and agammaglobulinemia patients.

Authors:  Yasser Bagheri; Ahmad Vosughi; Gholamreza Azizi; Reza Yazdani; Fatemeh Kiaee; Nasim Hafezi; Shahriar Alimorad; Majid Khoshmirsafa; Farhad Seif; Gholamreza Hassanpour; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  Immunol Lett       Date:  2019-05-03       Impact factor: 3.685

9.  X-linked agammaglobulinemia (XLA):Phenotype, diagnosis, and therapeutic challenges around the world.

Authors:  Zeinab A El-Sayed; Irina Abramova; Juan Carlos Aldave; Waleed Al-Herz; Liliana Bezrodnik; Rachida Boukari; Ahmed Aziz Bousfiha; Caterina Cancrini; Antonio Condino-Neto; Ghassan Dbaibo; Beata Derfalvi; Figen Dogu; J David M Edgar; Brian Eley; Rasha Hasan El-Owaidy; Sara Elva Espinosa-Padilla; Nermeen Galal; Filomeen Haerynck; Rima Hanna-Wakim; Elham Hossny; Aydan Ikinciogullari; Ebtihal Kamal; Hirokazu Kanegane; Nadia Kechout; Yu Lung Lau; Tomohiro Morio; Viviana Moschese; Joao Farela Neves; Monia Ouederni; Roberto Paganelli; Kenneth Paris; Claudio Pignata; Alessandro Plebani; Farah Naz Qamar; Sonia Qureshi; Nita Radhakrishnan; Nima Rezaei; Nelson Rosario; John Routes; Berta Sanchez; Anna Sediva; Mikko Rj Seppanen; Edith Gonzalez Serrano; Anna Shcherbina; Surjit Singh; Sangeetha Siniah; Guiseppe Spadaro; Mimi Tang; Ana Maria Vinet; Alla Volokha; Kathleen E Sullivan
Journal:  World Allergy Organ J       Date:  2019-03-22       Impact factor: 4.084

10.  Mutations in topoisomerase IIβ result in a B cell immunodeficiency.

Authors:  Lori Broderick; Shawn Yost; Dong Li; Matthew D McGeough; Laela M Booshehri; Marisela Guaderrama; Susannah D Brydges; Karolina Kucharova; Niraj C Patel; Margaret Harr; Hakon Hakonarson; Elaine Zackai; Ian G Cowell; Caroline A Austin; Boris Hügle; Corinna Gebauer; Jianguo Zhang; Xun Xu; Jian Wang; Ben A Croker; Kelly A Frazer; Christopher D Putnam; Hal M Hoffman
Journal:  Nat Commun       Date:  2019-08-13       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.